Novo Nordisk
Danish pharmaceutical giant and global leader in diabetes and obesity care
Novo Nordisk – WikipediaNovo Nordisk A/S is a global pharmaceutical and healthcare company headquartered in Bagsværd, Copenhagen, Denmark. Founded through the merger of two Danish insulin companies originally established in 1923 and 1925, the company today employs approximately 64,974 people and trades on the Copenhagen Stock Exchange (ticker: NOVO B). Its market capitalization notably exceeded the GDP of Denmark's domestic economy in 2023, making it the highest-valued company in Europe.
The company's core focus spans diabetes care, obesity treatment, haemophilia, and growth hormone therapies. Key products include insulin formulations (Tresiba, Levemir, NovoRapid), GLP-1 receptor agonists (Ozempic, Victoza, Wegovy, Rybelsus), haemophilia treatments (NovoSeven), and growth hormone therapies (Norditropin). Semaglutide — sold under multiple brand names for type 2 diabetes and obesity — accounted for nearly 70% of top-line revenue in 2024.
Novo Nordisk holds approximately 55% value market share in the global GLP-1 segment and over 70% share in branded obesity care as of 2024. For fiscal year 2024, the company reported revenue of DKK 290.4 billion (~$42.1 billion USD), a 25% increase year-over-year, and earnings of approximately DKK 101 billion (~$14.5 billion USD).
The company is majority-controlled by Novo Holdings A/S, the investment arm of the Novo Nordisk Foundation, which also funds broader biomedical research. As a dominant player in metabolic disease treatments — an area seeing rapid pharmaceutical innovation — Novo Nordisk is highly attuned to developments in drug delivery, biologics manufacturing, and digital health.
Ideas that could help Novo Nordisk
- SLC25A45-Based GLP-1RA Response Diagnostic
A diagnostic test to identify patients who are likely to be resistant to GLP-1 receptor agonist (GLP-1RA) weight-loss drugs based on SLC25A45 genetic variants or expression levels.
Why it helps: As a primary manufacturer of GLP-1RAs, they can improve drug efficacy rates by identifying non-responders via a companion diagnostic.
- SLC25A45-Based GLP-1RA Responder Diagnostic
A companion diagnostic that uses SLC25A45 genetic variants and plasma trimethyllysine-to-carnitine ratios to predict whether a patient will lose adipose tissue on GLP-1 receptor agonist therapy (e.g., semaglutide, tirzepatide) before expensive treatment begins.
Why it helps: As the manufacturer of semaglutide (Ozempic/Wegovy), Novo Nordisk would benefit from a companion diagnostic that identifies likely responders, strengthening the clinical value proposition and potentially supporting label expansion or reimbursement negotiations.